Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth

Oncotarget

Volumn 7, Issue 30, 2016, Pages 47479-47493

  Vittorio, Orazio ^a,b   Brandl, Miriam ^a,b   Cirillo, Giuseppe ^c   Kimpton, Kathleen ^a   Hinde, Elizabeth ^d   Gaus, Katharina ^d   Yee, Eugene ^e   Kumar, Naresh ^e   Duong, Hien ^b,e   Fleming, Claudia ^a   Haber, Michelle ^a   Norris, Murray ^a,b   Boyer, Cyrille ^b,e   Kavallaris, Maria ^a,b  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF CALABRIA   (Italy)

^d LA TROBE UNIVERSITY   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Catechin; Childhood cancer; Copper metabolism; Copper transporter

Indexed keywords

ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CATECHIN DEXTRAN CONJUGATE; COPPER; COPPER TRANSPORTER 1; GLUTATHIONE; UNCLASSIFIED DRUG; CATECHIN; CATION TRANSPORT PROTEIN; DEXTRAN; SLC31A1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL LEVEL; CONTROLLED STUDY; COPPER METABOLISM; DRUG DOSE COMPARISON; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IMR 32 CELL LINE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEPLETION; PROTEIN EXPRESSION; SH SY5Y CELL LINE; TREATMENT DURATION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CATECHIN; CATION TRANSPORT PROTEINS; CELL SURVIVAL; COPPER; DEXTRANS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEUROBLASTOMA; OXIDATIVE STRESS;

EID: 84982801387     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10201     Document Type: Article

References (47)

1. Matthay KK, George RE, Alice LY. Promising therapeutic targets in neuroblastoma. Clin Cancer Res. 2012; 18: 2740-2753.
2. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008; 9:247-256.
3. Tachibana H. Green tea polyphenol sensing. Proc Jpn Acad B, Phys Biol Sci. 2011; 87:66.
4. Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, Suganuma M, Fujiki H, Moriwaki H. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev. 2008; 17:3020-3025.
5. Fujiki H, Suganuma M, Imai K, Nakachi K. Green tea: cancer preventive beverage and/or drug. Cancer Lett. 2002; 188:9-13.
6. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006; 66:1234-1240.
7. Santilli G, Piotrowska I, Cantilena S, Chayka O, D'Alicarnasso M, Morgenstern DA, Himoudi N, Pearson K, Anderson J, Thrasher AJ. Polyphenol E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells. Clin Cancer Res. 2013; 19:1116-1125.
8. Renouf M, Marmet C, Guy PA, Beaumont M, Lepage M, Williamson G, Dionisi F. Dose-repsone plasma appearance of green tea catechins in adults. Mol Nutr Food Res. 2013; 57:833-839.
9. Cirillo G, Vittorio O, Hampel S, Spizzirri UG, Picci N, Iemma F. Incorporation of carbon nanotubes into a gelatincatechin conjugate: innovative approach for the preparation of anticancer materials. Int J Pharm. 2013; 446:176-182.
10. Vittorio O, Cirillo G, Iemma F, Di Turi G, Jacchetti E, Curcio M, Barbuti S, Funel N, Parisi OI, Puoci F. Dextrancatechin conjugate: a potential treatment against the pancreatic ductal adenocarcinoma. Pharm Res. 2012; 29:2601-2614.
11. Sagnella SM, Duong H, MacMillan A, Boyer C, Whan R, McCarroll JA, Davis TP, Kavallaris M. Dextran-based doxorubicin nanocarriers with improved tumor penetration. Biomacromolecules. 2013; 15:262-275.
12. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13:714-726.
13. Beck WT. The cell biology of multiple drug resistance. Biochem Pharmacol. 1987; 36:2879-2887.
14. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31:1869-1883.
15. Narayanan G, Bharathidevi S, Vuyyuru H, Muthuvel B, Konerirajapuram Natrajan S. CTR1 silencing inhibits angiogenesis by limiting copper entry into endothelial cells. PloS one. 2013; 8:e71982.
16. Kuo MT, Fu S, Savaraj N, Chen HH. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res. 2012; 72:4616-4621.
17. Brandl MB, Pasquier E, Li F, Beck D, Zhang S, Zhao H, Kavallaris M, Wong ST. Computational analysis of imagebased drug profiling predicts synergistic drug combinations: Applications in triple-negative breast cancer. Mol Oncol. 2014; 8:1548-1560.
18. Ding X, Xie H, Kang YJ. The significance of copper chelators in clinical and experimental application. J Nutr Biochem. 2011; 22:301-310.
19. Eisses JF, Kaplan JH. The mechanism of copper uptake mediated by human CTR1: a mutational analysis. J Biol Chem. 2005; 280:37159-37168.
20. Lambert JD, Elias RJ. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch Biochem Biophys. 2010; 501:65-72.
21. Hayakawa F, Ishizu Y, Hoshino N, Yamaji A, Ando T, Kimura T. Prooxidative activities of tea catechins in the presence of Cu2+. Biosci Biotechnol Biochem. 2004; 68:1825-1830.
22. Myant KB, Cammareri P, McGhee EJ, Ridgway RA, Huels DJ, Cordero JB, Schwitalla S, Kalna G, Ogg E-L, Athineos D. ROS production and NF-kB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell. 2013; 12:761-773.
23. Stringari C, Cinquin A, Cinquin O, Digman MA, Donovan PJ, Gratton E. Phasor approach to fluorescence lifetime microscopy distinguishes different metabolic states of germ cells in a live tissue. Proc Natl Acad Sci. 2011; 108:13582-13587.
24. Wright BK, Andrews LM, Jones MR, Stringari C, Digman MA, Gratton E. Phasor-FLIM analysis of NADH distribution and localization in the nucleus of live progenitor myoblast cells. Microscopy Res Tech. 2012; 75:1717-1722.
25. Bird DK, Yan L, Vrotsos KM, Eliceiri KW, Vaughan EM, Keely PJ, White JG, Ramanujam N. Metabolic mapping of MCF10A human breast cells via multiphoton fluorescence lifetime imaging of the coenzyme NADH. Cancer Res. 2005; 65:8766-8773.
26. Stringari C, Nourse JL, Flanagan LA, Gratton E. Phasor fluorescence lifetime microscopy of free and protein-bound NADH reveals neural stem cell differentiation potential. PloS One. 2012; 7:e48014.
27. Maryon EB, Molloy SA, Kaplan JH. Cellular glutathione plays a key role in copper uptake mediated by human copper transporter 1. Am J Physiol Cell Physiol. 2013; 304:C768-C779.
28. Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, Yung KY, Brenner D, Knobbe-Thomsen CB, Cox MA. Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression. Cancer Cell. 2015; 27:211-222.
29. Montero AJ, Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs. 2011; 71:1385-1396.
30. Cheng AJ, Cheng NC, Ford J, Smith J, Murray JE, Flemming C, Lastowska M, Jackson MS, Hackett CS, Weiss WA. Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma. Eur J Cancer. 2007; 43:1467-1475.
31. Qiu J. Traditional medicine: a culture in the balance. Nature. 2007; 448:126-128.
32. Tsao A, Liu D, Martin J, Tang X, Lee J, El-Naggar A, Wistuba I, Culotta K, Mao L, Gillenwater A. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res. 2009; 2:931-941.
33. Prochazkova D, Bousova I, Wilhelmova N. Antioxidant and prooxidant properties of flavonoids. Fitoterapia. 2011; 82:513-523.
34. Iwasaki Y, Hirasawa T, Maruyama Y, Ishii Y, Ito R, Saito K, Umemura T, Nishikawa A, Nakazawa H. Effect of interaction between phenolic compounds and copper ion on antioxidant and pro-oxidant activities. Toxicol in Vitro. 2011; 25:1320-1327.
35. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Rad Biol Med. 2010; 49:1603-1616.
36. Davison CA, Durbin SM, Thau MR, Zellmer VR, Chapman SE, Diener J, Wathen C, Leevy WM, Schafer ZT. Antioxidant enzymes mediate survival of breast cancer cells deprived of extracellular matrix. Cancer Res. 2013; 73:3704-3715.
37. Michaelis M, Kleinschmidt MC, Barth S, Rothweiler F, Geiler J, Breitling R, Mayer B, Deubzer H, Witt O, Kreuter J. Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem Pharmacol. 2010; 79:130-136.
38. Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev. 2009; 35:32-46.
39. Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, Knapp S, Xiao K, Campbell SL, Thiele DJ. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature. 2014; 509:492-496.
40. Jain S, Cohen J, Ward M, Kornhauser N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham M. Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Ann Oncol. 2013:mds654.
41. Tapiero H, Townsend D, Tew K. Trace elements in human physiology and pathology. Copper. Biomed Pharmacother. 2003; 57:386-398.
42. Desai V, Kaler SG. Role of copper in human neurological disorders. Am J Clin Nutr. 2008; 88:855S-858S.
43. Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, Norris MD, Trahair T, Andre N, Kavallaris M. beta-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer. 2013; 108:2485-2494.
44. Vittorio O, Brandl M, Cirillo G, Spizzirri UG, Picci N, Kavallaris M, Iemma F, Hampel S. Novel functional cisplatin carrier based on carbon nanotubesâ"quercetin nanohybrid induces synergistic anticancer activity against neuroblastoma in vitro. RSC Adv. 4:31378-31384.
45. McCarroll JA, Gan PP, Erlich RB, Liu M, Dwarte T, Sagnella SS, Akerfeldt MC, Yang L, Parker AL, Chang MH. TUBB3/bIII-Tubulin Acts through the PTEN/AKT Signaling Axis to Promote Tumorigenesis and Anoikis Resistance in Non-Small Cell Lung Cancer. Cancer Res. 2014; 75:415-425.
46. Quail JF, Tsai C-Y, Howell SB. Characterization of a monoclonal antibody capable of reliably quantifying expression of Human Copper Transporter 1 (hCTR1). J Trace Elem Med Biol. 2014; 28:151-159.
47. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci. 2003; 100:7977-7982.